

DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

December 17, 2020

MO HealthNet

[Join Webex Meeting](#)

[* Click HERE for Meeting Documents *](#)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
	Old Business	
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
	New Business	
10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Josh Moore
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	
11:00 – 11:45	Clinical and Fiscal Edits	Josh Moore
	<u>Existing Criteria</u>	
	i. 15 Day Supply – Oral Oncology Fiscal Edit	
	ii. Acetaminophen Cumulative Dose Clinical Edit	
	iii. BiDiI Clinical Edit	
	iv. Butalbital Combinations Excessive Therapy Edit	
	v. Butalbital Combinations without Codeine Clinical Edit	
	vi. Corlanor Clinical Edit	
	vii. Entresto Clinical Edit	
	viii. Selzentry Clinical Edit	
	<u>New Criteria or Revision of Existing Criteria</u>	
	i. 15 Day Supply Fiscal Edit	
	ii. Antipsychotics – 1 st Generation (Typical) Clinical Edit	
	iii. Antipsychotics – 2 nd Generation (Atypical) Clinical Edit and Reference List	
	iv. Benzodiazepines (Select Oral) Clinical Edit	
	v. Biosimilar vs Reference Products Fiscal Edit	
	vi. CAR T-Cell Therapy Clinical Edit	
	vii. Diabetic Supply Quantity Limit Fiscal Edit	
	viii. Duchenne Muscular Dystrophy (DMD) Clinical Edit	
	ix. High Cost Medication Kits Fiscal Edit	

- x. High Risk Therapies Clinical Edit – *NEW*
- xi. Isturisa Clinical Edit – *NEW*
- xii. Morphine Milligram Equivalent Accumulation Clinical Edit
- xiii. Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit – *NEW*
- xiv. Non-Oral Contraceptives Fiscal Edit
- xv. Opioids – Short-Acting Combinations Clinical Edit
- xvi. Opioids – Short-Acting Single Agents Clinical Edit
- xvii. Out-of-State, Non-Bordering Pharmacies Fiscal Edit - *NEW*
- xviii. Psychotropic Medications Polypharmacy Clinical Edit
- xix. PrEP Fiscal Edit
- xx. Spinal Muscular Atrophy (SMA) Clinical Edit – *NEW*
- xxi. Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit

11:45 – 1:00

Preferred Drug List (PDL)

Josh Moore

Existing Criteria

- i. Alzheimer’s Agents
- ii. Antiandrogenic Agents
- iii. Antiemetic 5-HT3, NK1 and Other Select Agents, Non-Injectable
- iv. Antiemetic, THC Derivatives
- v. Anti-Parkinsonism MAO-B Inhibitor Agents
- vi. Hereditary Angioedema Agents
- vii. Opiate Emergency Reversal Agents

New Criteria or Revision of Existing Criteria

- i. Anticonvulsants, Dravet Syndrome – *NEW*
- ii. Antiemetic, 5-HT3 and NK1 Agents, Injectable
- iii. Anti-Migraine, Alternative Oral Agents
- iv. Anti-Migraine Serotonin (5-HT1) Receptor Agonists
- v. Antiretrovirals, Treatment Products (*Reference List*)
- vi. Anti-Parkinsonism Non-Ergot Dopamine Agonists
- vii. Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- viii. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors – *NEW*
- ix. Fibromyalgia Agents
- x. GI Motility Agents
- xi. Glucagon Agents
- xii. Neuropathic Pain Agents
- xiii. NSAID Agents
- xiv. Opiate Dependence Agents
- xv. Opioids, Long Acting
- xvi. Sedative Hypnotic Agents
- xvii. Skeletal Muscle Relaxants
- xviii. Somatostatic Agents – *NEW*
- xix. Tramadol-Like Agents
- xx. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors – *NEW*

- 1:00 – 1:15 **LUNCH**
- 1:15 – 1:30 **Program Utilization Information – Conduent Update** Jennifer Colozza
- i. Call Center Statistics
 - ii. CyberAccess User Statistics
 - iii. New Drug Statistics
 - iv. “Top 25” Drugs by Cost/Claims
- 1:30 – 1:50 **Other Business**

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.

NEXT MEETING: March 18, 2021

Meeting via WebEx unless
otherwise specified